AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected partner. A late-stage trial found that combining Tagrisso with Orpathys significantly extended the time patients lived without their disease worsening compared with Tagrisso alone.
The study tested the combination as an initial treatment for a specific group of patients with EGFR-mutated advanced non-small cell lung cancer whose tumors expressed moderate to high levels of the MET protein. The results could expand the role of Orpathys while reinforcing a Tagrisso franchise, which already ranks among AstraZeneca’s (NASDAQ:AZN) best-selling products.
Bull Case
The trial achieved a clinically important objective by demonstrating a significant improvement in progression-free survival. Patients receiving Tagrisso and Orpathys lived longer without their cancer worsening than those receiving Tagrisso alone. The comparison is particularly meaningful because the trial tested Tagrisso plus Orpathys against Tagrisso alone, an established first-line treatment option for these patients, and showing an improvement over Tagrisso by itself suggests that adding Orpathys could provide extra benefit for the biomarker-defined population studied.
The combination was evaluated in patients who had not previously received treatment for their advanced lung cancer. Success in this first-line setting could be commercially important because it positions the therapy for use earlier in the treatment process rather than only after another medicine stops working. The company also reported encouraging overall-survival benefits, an important secondary objective. That description does not establish that the overall-survival result was statistically significant, but it suggests that the progression-free survival benefit was not accompanied by an unfavorable early survival trend.
Lead principal investigator Yi-Long Wu said the observed clinical benefit could reshape initial treatment for this distinct patient population. His statement reflects an investigator’s assessment rather than a regulatory conclusion, but it highlights the potential importance of addressing both EGFR mutations and elevated MET expression from the beginning of treatment.
The results could also strengthen AstraZeneca’s broader growth strategy, as cancer medicines contribute nearly half of the company’s sales, while Tagrisso is one of its leading products. Expanding its use through an effective combination could help AstraZeneca pursue its target of $80 billion in total annual sales by 2030. Orpathys also provides an additional opportunity. AstraZeneca is developing the drug with Hutchmed, and positive late-stage results could support its role alongside an established oncology product.
Bear Case
It is significant to note that the eligible population is narrowly defined in this case. The study involved previously untreated patients with EGFR-mutated advanced non-small cell lung cancer whose tumors had moderate to high MET expression, and so the results should not be extended to all lung-cancer patients or even every patient with an EGFR mutation.
Safety information could be another significant factor to consider. AstraZeneca said the combination’s safety profile was consistent with the known profiles of Tagrisso and Orpathys, with no new safety findings. However, detailed adverse-event results have not yet been presented, so the full tolerability comparison remains unavailable. Finally, a successful late-stage study does not by itself establish regulatory approval or commercial adoption, and much would depend on AstraZeneca and Hutchmed’s application plans, regulatory timelines, and expected sales from the combination.
Conclusion
The Tagrisso-Orpathys combination delivered a positive late-stage result against an active first-line treatment, giving AstraZeneca a potentially stronger option for a specific biomarker-defined lung-cancer population. The progression-free survival result and encouraging early overall-survival finding support the clinical case.
The size of the opportunity remains uncertain until the companies release detailed efficacy and safety data and outline their regulatory plans. For now, the trial strengthens AstraZeneca’s oncology pipeline, but its contribution to the company’s $80 billion ambition cannot yet be quantified.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
